n Days 2.7 Days 8.28 Days 29-120 Treatment Fdlow.up• Follow-up“ Ertl-3431 lg QD, Treatment 2g QD, Regimen EPB348 am ictig , —VV 1 g TID, Masan Study De* 0 Non infericoty stud/ (Valac,olovir as comparator) O60% powered with respect toprimly endpoint O Rardomued, double-Wind, acuve-contnolled,mulb-ce